Typewriter Therapeutics is a biotech startup developing RNA-based genetic medicines intended for patients with cancer, autoimmune diseases, and severe genetic disorders. Its Target-Primed Reverse Transcription (TPRT) platform, built on the R2 retrotransposon discovered by University of Tokyo researchers, uses lipid-nanoparticle-delivered RNA to insert whole therapeutic genes at specific genomic sites without viruses, aiming for safer, durable, and re-dosable medicines. Founded in 2022 and operating from Cambridge, Massachusetts and Tokyo, the company is initially targeting in vivo CAR T therapies and genetic liver diseases.
1
Round
1
Industry
5
Tags
Sep 2, 2026
Latest raise
Funding activity · 1 round
Sep 2, 2026
$56M
Series A
Led by AN Venture Partners
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
